Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546765 | 0.90 | TSHR (0.51) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL5535044 | 0.88 | TSHR (0.50) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL67262 | 0.87 | TSHR (0.49) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL5542239 | 0.87 | KCNH2 (0.49) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL5535027 | 0.87 | KCNH2 (0.49) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL1211 | 0.81 | IDO1 (0.61) | TSHRIDO1LOXL2AKR1C3ALDH1A1 | |
| SCHEMBL3656180 | 0.81 | TSHR (0.62) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL5535836 | 0.80 | TSHR (0.54) | TSHRALDH1A1CYP2C19POLB | |
| SCHEMBL3292782 | 0.78 | TSHR (0.75) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL4985766 | 0.78 | TSHR (0.58) | TSHRKCNH2IDO1KCNJ1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | claimed |
| EP-1379698-B1 | MOBILITY-MODIFIED NUCLEOBASE POLYMERS AND METHODS OF USING SAME | APPLIED BIOSYSTEMS LLC (US) | 2009-08-26 | — | — | EP | claimed |
| EP-0898575-B1 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT DR (US) | 2004-12-29 | — | — | EP | claimed |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-10-16 | — | — | US | claimed |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-03-20 | — | — | US | claimed |
| US-20020169281-A1 | Peptoids incorporating chemoselective functionalities | CHIRON CORPORATION | 2002-11-14 | — | — | US | claimed |
| WO-2002081637-A2 | PEPTIDES INCORPORATING CHEMOSELECTIVE FUNCTIONALITIES | CHIRON CORPORATION (US) | 2002-10-17 | — | — | WO | claimed |
| US-6075143-A | USEFUL FOR FORMING PEPTIDE NUCLEIC ACIDS OR HYBRID OF PEPTIDE NUCLEIC ACIDS AND DEOXYNUCLEIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| US-5817811-A | AMIDATION OF THE CORRESPOND ESTERIFIED AMINE COMPOUND WITH A CARBOXYLATED NUCLEOTIDE BASE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| EP-0672661-A1 | Substituted N-ethyl-glycinderivatives for the preparation of PNA and PNA-/DNA hybrides | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| EP-0036673-A1 | New thiadiazol compounds and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-30 | — | — | EP | disclosed |
| US-4268509-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-19 | — | — | US | disclosed |
| EP-0027599-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | ADAR, RNMT, ATIC | TSHR 1687/4885KCNH2 4326/4885IDO1 3754/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | TSHR 1572/4885KCNH2 3274/4885IDO1 2317/4885 |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, LYN | TSHR 2081/4885KCNH2 3009/4885IDO1 1985/4885 |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | ADAR, RNMT, RRM1 | TSHR 1523/4885KCNH2 4404/4885IDO1 3555/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | TSHR 3820/4885KCNH2 4430/4885IDO1 1832/4885 |
| US-20020169281-A1 | Peptoids incorporating chemoselective functionalities | VIP, PCNA, DNPEP | TSHR 2487/4885KCNH2 4391/4885IDO1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.